DDInter1631 DDInter1952
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Xylometazoline is an alkylbenzene.
Xylometazoline {u} (Compound) resembles {v} (Compound) Tymazoline
Xylometazoline {u} (Compound) binds {v} (Gene) ADRA1D
Xylometazoline {u} (Compound) downregulates {v} (Gene) STUB1
Xylometazoline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amoxapine
Xylometazoline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Xylometazoline {u} may lead to a major life threatening interaction when taken with {v} Methylergometrine
Xylometazoline {u} may lead to a major life threatening interaction when taken with {v} Iobenguane
Xylometazoline (Compound) resembles Tymazoline (Compound)
Xylometazoline (Compound) binds ADRA1D (Gene)
Xylometazoline (Compound) downregulates STUB1 (Gene)
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine
Xylometazoline may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Xylometazoline may lead to a major life threatening interaction when taken with Methylergometrine
Xylometazoline may lead to a major life threatening interaction when taken with Iobenguane